Our current R&D program within Inflammatory Conditions will focus on the development of important tools to investigate inflammatory components in relation to different disease areas. Bioneer will work on digital histological methods to evaluate relevant inflammatory cell populations, develop macrophage-specific in vitro models and set-up a test bed for developing and evaluating sensitive technologies for detecting biomarkers in liquid biopsies.
The R&D groups are located at the Bioneer headquarter facilities, where we have access to various instruments and a broad palette of analytical equipment essential for the R&D program.
During the last couple of years, there has been an increasing attention to understanding the complex role of and interaction with the immune system of different pharmaceutical drugs. Bioneer will therefore develop services to support better documentation of drug effects and Mode of Action in inflammatory conditions.
Advanced predictive disease models are key for pharmacological screening and drug development. Bioneer develops platforms simulating immunosuppressive conditions as found in cancer. These models are based on interactions between tolerogenic dendritic cells (DC) and T-cells in an allogenic mixed lymphocyte reaction (MLR) assay. In addition, we focus on purification and development of different immunosuppressive immune subsets including regulatory T-cell and macrophages.
Automated multiplex stainings of antibodies, RNA and protein markers will be carried out on relevant inflammatory targets. For different inflammatory diseases, a combination of inflammatory parameters will be identified and analyzed via advanced scanner -and digital image technologies. The digital histology, which allows for visual separation between immune cell populations, will be validated on retrospective clinical study samples.
Bioneer will strengthen our knowledge around molecular and cellular assays for sensitive detection in liquid biopsies through in-depth mapping and evaluation of available state-of-the-art technologies currently on the market. The activities will mainly cover detection of DNA, RNA, protein or cell components in blood samples.
For further information, please contact Kim Holmstrøm, R&D Manager, Molecular Detection by email.
Bioneer aims at establishing a validated macrophage model, where the different macrophage cell types can be stimulated to reflect the situation in patients with different inflammatory diseases including cancer. Thus, the pro-inflammatory (M1), anti-inflammatory (M2) and cancer-promoting qualities of the macrophage can be studied under different conditions in this in vitro cell model, which complement the in vitro DC / T cell models that Bioneer already have developed.
Immune suppressor assays predicating suppressive capacity of different cellular subsets/products is highly relevant for development of diverse biopharmaceuticals. Such Bioassays can be used as mode of action studies for suppressive immune subsets such as: regulatory T cells, macrophages, myeloid-derived suppressor cell and mesenchymal stromal cells among others. As a second layer the suppressor assays can be used as advanced bioassays testing the immunomodulatory effect of a certain drug which e.g. aim to reverse or further stimulate the suppressive function.
> Cardiology Stem Cell Center
Bioneer is part of the Cardiology Stem Cell Center (CSCC) granted 25 MDKK by the Innovation Fund Denmark (IFD). The aim of CSCC is to solve an unmet need for novel, effective treatments of patients with ischemic heart disease and heart failure by use of adipose-derived stem cells from healthy donors. The grant from IFD is to be used to develop stem-cell treatment and to gather the documentation required by the European Medicines Agency for a new drug to be approved for general patient treatment. Read more in the press release here.
> MVA Oncology Network
Bioneer is member of the Medicon Valley Alliance Oncology Network, which is a professional and social network within oncology initiated by professors and entrepreneurs Nils Brünner (University of Copenhagen, DK) and Carl Borrebaeck, (Lund University, SE). The network focuses on best practice, experience and current challenges for public-private collaboration and the commercialization of oncology related R&D in the Medicon Valley region.
circRTrain is a Marie Curie Innovative Training Network (ITN) funded by the European Union within the H2020 Programme. Bioneer is one of several partners of circRTrain representing universities, research institutions and companies located in Germany, Italy, Spain, Israel, Denmark and in the Netherlands. The programme started in January 2017 and will continue for four years. Read more here.
> Danish Biomarker Network
Bioneer is also one of the initiators to the Danish Biomarker Network together with BioPeople, Denmark’s Life Science Cluster organization. The initiative’s aim is to provide better opportunities in Denmark for prevention of diseases, diagnosis and treatment by usage of biomarkers in a cross-disciplinary fashion. The Network is currently investigating the possibility to set up a Danish infrastructure on biomarker research and development in a public-private partnership model. Read more here.
Johansen, EM., Juhl, M., Ekblond, A., Gad, M., Larsen, J. (2018) Mesenchymal stromal cells as an advanced therapy medicinal product (ATMP) – GMP
production and immunological potency assays. LS Dansk Biotek Magazine 4: 4-6. DANSK BIOTEK
Thorlacius-Ussing, G., Nielsen, BS., Andersen, V., Holmstrøm, K., Pedersen, AE. (2017) Expression and Localization of miR-21 and miR-126 in Mucosal Tissue from Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 23, 739-752. Pubmed
Follin, B., Juhl, M., Cohen, S., Pedersen, AE., Gad, M., Kastrup, J., Ekblond, A. (2015) Human adipose-derived stromal cells in a clinically applicable injectable alginate hydrogel: Phenotypic and immunomodulatory evaluation. Cytotherapy 17(8):1104-18. Pubmed
Pedersen, AE., Holmstrøm, K., Jørgensen. F., Jensen, SS., and Gad, M. (2014) Development of assay platforms for in vitro screening of Treg
modulating potential of pharmacological compounds. Immunopharmacol Immunotoxicol 37(1):63-71. Pubmed
Nielsen, BS., Balslev, E., Svenstrup Poulsen, T., Nielsen, D., Møller, T., Ehlers Mortensen, C., Holmstrøm, K., Høgdall, E. (2014) miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer. Front Oncol 4:207. Pubmed
Jensen, SS., Gad, M. (2010) Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity. J Inflamm 7:37. Pubmed
Create new product opportunities
We offer access to essential tools, technology and unique biological resources within cell and molecular biology.